Brii Biosciences expands HBV deal with VBI around immunotherapeutic, vaccine

Five years after bagging China rights to VBI Vaccines’ hepatitis B therapy and teaming up on its development, Brii Biosciences is going for the whole thing.

In an expanded deal, Brii has decided to acquire worldwide rights to VBI-2601, an immunotherapeutic candidate…
Click here to view original post

Advertisement — Advertise with Biotech Networks